Immunology
4 years ago
“We remain cautiously optimistic that we will have a safe, effective vaccine based on animal studies.” Here is an up-to-date list of COVID-19 trials as discussed at #ACR20 by Dr. A. Fauci @RheumNow https://t.co/DAoLGGtw1A
Fauci: Common endpoints, common parameters provide "bridge" between #COVID19 vaccine trials. "We are cautiously optimistic" for a vaccine "by the end of the calendar year" because of favorable animal studies, though distribution will be later #ACR20 @Rheumnow. https://t.co/vPLEYiGKam
4 years ago
A reminder or the fundamentals to curbing COVID19 per Dr. Anthony Fauci at #ACR20:
1. Everyone needs to wear a mask
2. Maintain 6 feet distance from others
3. Avoid crowds & congregations
4. Outdoor better than indoors
5. Wash your hands frequently
@RheumNow @LCalabreseDO https://t.co/khLS7V2A3b
4 years ago
Data from MUSE & TULIP trials of #anifrolumab in #SLE show increased risk of #herpeszoster when compared to placebo. Most HZ events mild-moderate, cutaneous and resolved without discontinuation of drug.
#RheumTwitter #lupus
Abs#0849 #ACR20 @RheumNow
https://t.co/8a6OcZmOso
4 years ago
Valerio et al find 40% of 294 patients w/ #rheumaticdisease refuse or are uncertain about getting inactivated #influenza #vaccine. Key determinants of #vaccinehesitancy found to be concerns about adverse events, safety & efficacy.
Abs#0632 #ACR20 @RheumNow
https://t.co/f34DAc5WiN
4 years ago
In the search for biomarkers in PsA, interesting study showing absolute lymphocyte count is negatively correlated with cardiovascular disease risk score and red cell distribution width and increases with TNF-Inhibitor Therapy @rheumnow #ACR20 Abstr#878
4 years ago
Some great abstracts on #vaccine hesitancy in the #infection in #rheumaticdiseases poster session!
What's the greatest concern for patients offered #influenza & #pneumococcal vaccines?
How can we address these concerns & encourage vaccine uptake? Comment below!
#ACR20 @RheumNow
4 years ago
Tracking CRP in the hyper-acute phase of admission for #COVID19 predictive of progression to critical illness- suggests trends of inflammatory biomarkers, not absolute admission values, may be most useful for triage & therapy.
Abs#0626 #ACR20 @RheumNow
https://t.co/E14y3e4ALi
4 years ago
Patients with ARDs have incr. susceptibility to #infection. Real-world study shows suboptimal #influenza, #pneumococcal & #herpeszoster #vaccination coverage in these patients. Important to consider strategies to improve uptake.
Abs#0541 #ACR20 @RheumNow
https://t.co/GAapkzILvW
Avacopan - C5a Receptor Inhibitor - in ANCA-Associated Vasculitis: Dr. Arthur Kavanaugh
San Diego-based rheumatologist Dr. Arthur Kavanaugh takes a closer look at plenary session Abstract #0432 presented Friday at ACR 2020.